Diagnosis, treatment and genetic analysis of a case of familial aldosteronism type II with WFS1 gene mutation
Received date: 2022-08-09
Revised date: 2022-09-12
Online published: 2022-09-22
Primary aldosteronism (PA) is a disease characterized by hypertension and hypokalemia due to the excessive aldosterone secretion from the adrenal cortex, which leads to the retention of both water and sodium, and the inhibition of the renin-angiotensin system as well. Familial hyperaldosteronism type II (FH-II) is known as an autosomal dominant hereditary disease, which is a scarce cause of PA. In this report, we cllected the clinical data of a patient with repeated hypertension and hypokalemia of uncertain diagnosis since 2014. Nevertheless, we discovered by genetic sequencing in 2021 that the CLCN2 and WFS1 gene mutation of the patient, whose mother belongs to heterozygote genotype and father belongs to wild-type genotype. Combined with a series of endocrine function tests and imaging studies, the patient was finally certified her suffering from FH-II and WFS1 gene mutation. By summarizing and analyzing the characteristics and genetic test results of this case, we recommended gene sequencing for patients with PA whose etiology is difficult to be determined clinically. This case also provides new clinical data for subsequent genetic studies of the disease.
Key words: familial hyperaldosteronism type II; CLCN2; WFS1
Zhilian Sun, Junying He, Xiaoling Cheng, Xiaoxia Tan, Weihua Wu . Diagnosis, treatment and genetic analysis of a case of familial aldosteronism type II with WFS1 gene mutation[J]. Hereditas(Beijing), 2022 , 44(11) : 1072 -1078 . DOI: 10.16288/j.yczz.22-197
| [1] | Chinese Society of Endocrinology.Expert consensus on the diagnosis and treatment of primary aldosteronism (2020). Chin J Endocrinol Metab, 2020, 36(9): 727-736. |
| [1] | 中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版). 中华内分泌代谢杂志, 2020, 36(9): 727-736. |
| [2] | Wang HP, Tong AL. Research progress on gene mutation related primary aldosteronism. International Journal of Endocrinology and Metabolism, 2021, 41(2): 87-90. |
| [2] | 王慧萍, 童安莉. 原发性醛固酮增多症相关的基因突变研究进展. 国际内分泌代谢杂志, 2021, 41(2): 87-90. |
| [3] | Shaul O. How introns enhance gene expression. Int J Biochem Cell Biol, 2017, 91(Pt B):145-155. |
| [4] | Scholl UI, St?lting G, Schewe J, Thiel A, Tan H, Nelson- Williams C, Vichot AA, Jin SC, Loring E, Untiet V, Yoo T, Choi J, Xu SX, Wu AH, Kirchner M, Mertins P, Rump LC, Onder AM, Gamble C, Mckenney D, Lash RW, Jones DP, Chune G, Gagliardi P, Choi M, Gordon R, Stowasser M, Fahlke C, Lifton RP. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet, 2018, 50(3): 349-354. |
| [5] | Fernandes-Rosa FL, Daniil G, Orozco IJ, G?ppner C, El ZR, Jain V, Boulkroun S, Jeunemaitre X, Amar L, Lefebvre H, Schwarzmayr T, Strom TM, Jentsch TJ, Zennaro MC. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet, 2018, 50(3): 355-361. |
| [6] | Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, Feuchtinger A, Chortis V, Gilligan LC, Ludwig P, Riester A, Asbach E, Hughes BA, O'Neil DM, Bidlingmaier M, Tomlinson JW, Hassan-Smith ZK, Rees DA, Adolf C, Hahner S, Quinkler M, Dekkers T, Deinum J, Biehl M, Keevil BG, Shackleton CH, Deeks JJ, Walch AK, Beuschlein F, Reincke M. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2(8). |
| [7] | Wu VC, Chueh SJ, Chen L, Chang CH, Hu YH, Lin YH, Wu KD, Yang WS. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens, 2017, 35(8): 1698-1708. |
| [8] | Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, Lang K, Quack I, Rump LC, Willenberg HS, Beuschlein F, Quinkler M, Hannemann A. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. Eur J Endocrinol, 2015, 173(5): 665-675. |
| [9] | Panfili E, Mondanelli G, Orabona C, Belladonna ML, Gargaro M, Fallarino F, Orecchini E, Prontera P, Proietti E, Frontino G, Tirelli E, Iacono A, Vacca C, Puccetti P, Grohmann U, Esposito S, Pallotta MT. Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation. Hum Mol Genet, 2021, 30(3-4): 265-276. |
| [10] | Li MH, Wang SH, Xu KF, Chen Y, Fu Q, Gu Y, Shi Y, Zhang M, Sun M, Chen H, Han XQ, Li YX, Tang ZK, Cai LJ, Li ZQ, Shi YY, Yang T, Polychronakos C. High prevalence of a monogenic cause in Han Chinese diagnosed with type 1 diabetes, partly driven by nonsyndromic recessive WFS1 mutations. Diabetes, 2020, 69(1): 121- 126. |
| [11] | Yahaya TO, Salisu TF. A review of type 2 diabetes mellitus predisposing genes. Curr Diabetes Rev, 2019, 16(1): 52-61. |
| [12] | Gong X, Zhang C, Yiliyasi A, Shi Y, Yang XW, Nuersimanguli A, Guan YQ, Xu SH. A comparative analysis of genetic diversity of candidate genes associated with type 2 diabetes in worldwide populations. Hereditas(Beijing), 2016, 38(6): 543-559. |
| [12] | 弓弦, 张超, 伊利亚斯·艾萨, 时瑛, 杨雪唯, 努尔斯曼古丽奥斯曼, 关亚群, 徐书华. 2型糖尿病易感候选基因在世界不同人群中的多样性比较分析. 遗传, 2016, 38(6): 543-559. |
| [13] | Sch?fer SA, Müssig K, Staiger H, Machicao F, Stefan N, Gallwitz B, H?ring HU, Fritsche A. A common genetic variant in WFS1 determines impaired glucagon-like peptide- 1-induced insulin secretion. Diabetologia, 2009, 52(6): 1075-1082. |
/
| 〈 |
|
〉 |